At a glance
- Originator Allergan
- Class Antiglaucomas
- Mechanism of Action Alpha 2 adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 30 Jul 1998 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 04 Sep 1996 New profile
- 04 Sep 1996 Preclinical development for Glaucoma in USA (Ophthalmic)